AIV Logo AIV Assistant

Loading...

Earnings Recaps

Browse reported earnings of the most popular stocks

23 companies Today
Barnes Group Inc. logo
B
Barnes Group Inc.
B
Q2 2025
Reported:

Barrick Gold delivered a strong Q2 2025 performance, achieving the highest adjusted earnings per share since 2013 at $0.47, supported by improved production and strategic portfolio management. The company remains on track for an even stronger second half as cash flow and dividends increase.

Key takeaways
  • Adjusted earnings per share of $0.47, more than doubling from last year and reflecting robust operational performance.
  • Free cash flow improved significantly, bolstered by a favorable gold price and disciplined capital allocation.
  • Continued focus on Tier 1 assets with the completion of the $1 billion sale of the Donlin Gold project, enhancing growth opportunities.
  • Health and safety metrics showed marked improvement, with a 50% reduction in lost time injuries year-to-date.
  • Total dividends returned to shareholders reached $753 million in the first half, with an additional performance dividend on the way.
More info
Ballard Power Systems Inc. logo
BL
Ballard Power Systems Inc.
BLDP
Q2 2025
Reported:

Ballard Power Systems reported a solid 11% year-over-year revenue growth in Q2 2025, driven by significant improvements in gross margin and strategic restructuring efforts amid challenging market conditions.

Key takeaways
  • Revenue increased to $17.8 million, with particular strength in the rail vertical.
  • Gross margin expanded by 24 percentage points due to cost efficiencies from restructuring and reduced contract provisions.
  • Secured a landmark marine order post-quarter, underscoring ongoing momentum in customer engagement across key sectors.
  • Focused on becoming a sustainable cash flow positive business by the end of 2027, emphasizing operational efficiency and customer value.
  • Key initiatives such as Project Forge are on track, aiming to enhance production capabilities and reduce costs further.
More info
CoreCivic, Inc. logo
CX
CoreCivic, Inc.
CXW
Q2 2025
Reported:

CoreCivic reported strong second quarter 2025 results, with total revenue up 9.8% year-over-year and robust growth in adjusted EBITDA, driven by increased demand from federal detention populations.

Key takeaways
  • Adjusted EBITDA increased to $103.3 million, reflecting a 23.2% growth from the prior year.
  • Successful repurchase of 3.9 million shares year-to-date, totaling $81 million, demonstrating commitment to returning value to shareholders.
  • The company secured an acquisition of the Farmville Detention Center for $67 million, enhancing its portfolio with expected accretive earnings.
  • Positive outlook with revised full-year 2025 guidance, bolstered by federal funding initiatives and increased occupancy projections.
More info
Diversified Energy Company PLC logo
DE
Diversified Energy Company PLC
DEC.L
Q2 2025
Reported:

Diversified Energy's Q2 2025 results reflect a robust transformation driven by the Maverick acquisition, with nearly doubled year-over-year EBITDA and significant cash flow growth.

Key takeaways
  • Achieved a 65% increase in total proved reserves since year-end 2024, enhancing asset value.
  • Returned approximately $105 million to shareholders in dividends and share repurchases, representing 20% of current market capitalization.
  • Successfully reduced debt by approximately $130 million in H1 2025, reinforcing financial health.
  • Established a capital deployment partnership with Carlyle, positioning for up to $2 billion in future non-dilutive acquisitions.
  • Continued focus on strategic acquisitions and operational efficiencies, with increased guidance on run rate synergies post-Maverick integration.
More info
Dole plc logo
DO
Dole plc
DOLE
Q2 2025
Reported:

Dole plc reported robust Q2 2025 results with a 14.3% increase in revenue to $2.4 billion and a 12% growth in adjusted EPS, underscoring strong performance across all segments despite ongoing market challenges.

Key takeaways
  • Adjusted EBITDA rose 9.3% to $137 million, driven by strong growth in Diversified Fresh Produce and Fresh Fruit segments.
  • Completed the strategic sale of the Fresh Vegetable division, allowing for a more focused investment in core businesses.
  • North American operations showed strong volume growth in bananas and pineapples, although higher sourcing costs temporarily constrained profits.
  • Diversified EMEA segment adjusted EBITDA grew 15%, benefitting from strong demand and favorable currency impact.
  • Anticipate some cost pressures in the second half due to ongoing supply chain complexities and external market factors.
More info
Franco-Nevada Corporation logo
FN
Franco-Nevada Corporation
FNV
Q2 2025
Reported:

Franco-Nevada Corporation achieved record financial performance in Q2 2025, driven by high gold prices and successful asset integration, marking a continued strong growth trajectory.

Key takeaways
  • Revenue and adjusted EBITDA reached new highs, benefiting from average gold prices up 40% year-over-year.
  • Total GEOs sold increased 2% to 112,093, with significant contributions from recent acquisitions including Cote Gold and Porcupine.
  • Positive advancements in Panama and U.S. project permitting support robust growth outlook, with three projects moving ahead.
  • The company remains well-positioned for future expansion, bolstered by approximately $1.3 billion in annual cash flow generation and a solid pipeline of acquisition opportunities.
More info
Green Plains Inc. logo
GP
Green Plains Inc.
GPRE
Q2 2025
Reported:

Green Plains Inc. reported significant progress in Q2 2025, with enhancements in profitability drivers and strategic asset optimization, supported by favorable government policies boosting the renewable fuel sector.

Key takeaways
  • Achieved $50 million in cost reductions through operational efficiencies and streamlined SG&A expenses, with an aim to maintain low costs going forward.
  • Positive government policy developments, including the extension of the 45Z clean fuel production tax credit, are expected to bolster future profitability with anticipated annualized EBITDA contributions exceeding $150 million from decarbonization efforts.
  • Successfully exited noncore asset activities to focus on core operations, enhancing liquidity and optimizing future earnings potential.
  • The construction of the CCS infrastructure remains on track for a startup anticipated in Q4 2025, expected to generate consistent cash flows.
  • In the final stages of CEO search, with plans for leadership transition to align with the company's strategic objectives.
More info
Humacyte Inc. Common Stock logo
HU
Humacyte Inc. Common Stock
HUMA
Q2 2025
Reported:

Humacyte's second quarter 2025 results show significant growth following FDA approval of Symvess, evidenced by a surge in VAC approvals and expanded military sales, despite headwinds from recent CMS reimbursement challenges.

Key takeaways
  • Symvess commercial adoption accelerated, with 82 civilian hospitals now authorized to purchase, up from just 5.
  • Recorded July product sales of approximately $0.3 million surpassed total sales for the first half of 2025.
  • Secured ECAT approval from the U.S. Defense Logistics Agency, resulting in the first sale to a military facility and continued interest for additional contracts.
  • CMS denied the NTAP application for Symvess, which Humacyte believes will have limited impact due to the small percentage of Medicare patients affected.
  • ATEV Phase III trial results were well-received at a major medical conference, highlighting superior outcomes for patients at high risk of fistula nonmaturation.
More info
Karyopharm Therapeutics Inc. logo
KP
Karyopharm Therapeutics Inc.
KPTI
Q2 2025
Reported:

Karyopharm Therapeutics delivered solid Q2 2025 results, driven by strong commercial performance and significant progress in pivotal Phase III trials, positioning the company for potential transformative outcomes in myelofibrosis and endometrial cancer.

Key takeaways
  • Successfully completed enrollment in the Phase III SENTRY trial for myelofibrosis, marking a key milestone in the drug development timeline.
  • Positive preliminary safety data for the selinexor and ruxolitinib combination suggests enhanced tolerability compared to ruxolitinib alone.
  • Anticipation for top-line results in March 2026, with potential peak revenue estimates of $1 billion annually for selinexor in myelofibrosis in the U.S. market.
  • Continued engagement with lenders to enhance liquidity amidst financial constraints, underscoring efforts to maintain operational stability.
More info
Lument Finance Trust, Inc. logo
LF
Lument Finance Trust, Inc.
LFT
Q2 2025
Reported:

Lument Finance Trust reported stable earnings for Q2 2025 with net income of $0.05 per share and a quarterly dividend declaration of $0.06, reflecting steady portfolio management amidst a mixed economic backdrop.

Key takeaways
  • GAAP net income of $2.5 million ($0.05 per share) and distributable earnings also at $0.05 per share for Q2 2025.
  • Decline in net interest income to $7 million, attributed to principal loan repayments and reduced outstanding portfolio balances.
  • Portfolio credit ratings remained stable; proactive asset management strategies resulted in reduced specific reserves in line with expectations.
  • Significant increase in CRE CLO issuance volumes in H1 2025, signaling improved market liquidity and potential for future securitization opportunities.
  • Continued focus on refinancing and asset management strategies to maximize shareholder value despite economic uncertainties.
More info
monday.com Ltd. Ordinary Shares logo
MN
monday.com Ltd. Ordinary Shares
MNDY
Q2 2025
Reported:

monday.com delivered strong second-quarter results with a 27% revenue growth, driven by increasing demand for its platform and enhanced AI capabilities. The company also maintained robust operational efficiency, achieving a 15% non-GAAP operating margin.

Key takeaways
  • Total revenue for Q2 reached $299 million, marking a 27% year-over-year increase.
  • Non-GAAP operating margin improved to 15%, reflecting disciplined cost management.
  • monday CRM hit $100 million in annual recurring revenue, showcasing strong market traction.
  • Customer engagement with AI capabilities skyrocketed, with 46 million AI-driven actions taken since launch.
  • The company projected third-quarter revenues of $311 million to $313 million, indicating 24%-25% growth year-over-year.
More info
Niu Technologies logo
NI
Niu Technologies
NIU
Q2 2025
Reported:

Niu Technologies achieved a robust 37% year-over-year increase in sales volume during Q2 2025, primarily driven by significant gains in the Chinese market, though challenges in international sales persisted due to tariffs and competition.

Key takeaways
  • Total sales reached 350,000 units, with 318,000 units sold in China, marking a 54% increase year-over-year.
  • Revenue rose to RMB 1.26 billion, a 34% year-over-year growth, alongside an improved gross margin of 20.1%.
  • Net profit turned positive at RMB 5.9 million, reflecting ongoing strategic focus on profitability amid market challenges.
  • Product portfolio optimization led to an 11% increase in average selling price (ASP) compared to Q1 2025.
  • Continued investments in smart technology aim to enhance the driving experience and safety features across new product launches.
More info
Owens & Minor, Inc. logo
OM
Owens & Minor, Inc.
OMI
Q2 2025
Reported:

Owens & Minor reported robust growth in its Patient Direct business amid the planned divestiture of its Products & Healthcare Services segment, positioning the company for future profitability in the evolving home-based care market.

Key takeaways
  • Projected revenue for the Patient Direct segment is expected to reach between $2.76 billion and $2.82 billion in 2025, with adjusted EBITDA ranging from $376 million to $382 million.
  • The divestiture process for the Products & Healthcare Services segment is underway, allowing the company to concentrate on the higher-margin, higher-growth Patient Direct business.
  • Demographic trends underpinning the demand for home-based care are strong, with substantial growth potential driven by increasing chronic health conditions among American adults.
  • Despite the termination of the Rotech acquisition, management remains focused on selective acquisition opportunities to enhance Patient Direct capabilities.
  • Initiatives to drive revenue and EBITDA growth include advancements in IT infrastructure, revenue cycle improvements, and an expanded sales force.
More info
Pampa Energia S.A. logo
PA
Pampa Energia S.A.
PAM
Q2 2025
Reported:

Pampa Energia reported a Q2 2025 adjusted EBITDA of $239 million, a 17% decline year-on-year, influenced by softer gas sales and rising operating costs, despite improved production and contributions from new assets.

Key takeaways
  • Successful ramp-up at Rincón de Aranda, with average production increasing to 8,800 barrels per day by end of June, aiming for 20,000 barrels per day by Q4 2025.
  • Adjusted EBITDA fell 17% YoY driven by reduced gas sales and elevated operating expenses, although quarter-on-quarter results showed seasonal improvement.
  • Significant 134% YoY increase in capital expenditures to $354 million, primarily for Rincón de Aranda development.
  • Positive EBITDA recovery in petrochemical sector signaling gradual improvements in performance.
  • Gas exports to Chile increased, reaching 1.1 million cubic meters per day, capitalizing on competitive pricing against LNG.
More info
Pampa Energia S.A. logo
PA
Pampa Energia S.A.
PAMP.BA
Q2 2025
Reported:

Pampa Energia's Q2 2025 results showed a 17% decline in adjusted EBITDA to $239 million, primarily impacted by soft gas sales and increased operating expenses, while production ramp-up at Rincón de Aranda provided some offsetting factors.

Key takeaways
  • Adjusted EBITDA fell 17% year-on-year due to decreased gas sales and higher operational costs, despite contributions from the new 140 MW wind farm.
  • Capital expenditures surged 134% YoY to $354 million, primarily directed towards Rincón de Aranda's development.
  • Gas exports to Chile increased, with a significant production rebound occurring from Rincón de Aranda in June, which is projected to hit a capacity of 20,000 barrels per day by Q4 2025.
More info
Perion Network Ltd Common Stock logo
PE
Perion Network Ltd Common Stock
PERI
Q2 2025
Reported:

Perion Network's Q2 2025 earnings reflect a positive turning point with significant revenue growth in advertising solutions and successful integration of recent acquisitions, positioning the company towards its vision of becoming the go-to centralized platform for marketers.

Key takeaways
  • Non-search revenue from advertising solutions increased year-over-year, marking the first growth since Q3 2023.
  • Launch of the new performance CTV solution integrates performance metrics with CTV campaigns, enhancing accountability and ROI for advertisers.
  • Expansion of programmatic digital out-of-home partnerships in key APAC and EMEA markets increases market penetration in a rapidly growing sector.
  • Full integration of Greenbids is on track, adding AI capabilities that generate new synergies within the Perion One platform.
More info
RadNet, Inc. logo
RD
RadNet, Inc.
RDNT
Q2 2025
Reported:

RadNet, Inc. posted record revenue and adjusted EBITDA in Q2 2025, rebounding from previous disruptions, driven by advanced imaging growth and improved reimbursement rates.

Key takeaways
  • Q2 total revenue reached a record $498.2 million, up 8.4% year-over-year, with Digital Health segment revenue surging 30.9%.
  • Adjusted EBITDA increased 12.3% to a record $81.2 million, reflecting improved operational efficiency and margin expansion.
  • Advanced imaging procedures comprised 27.5% of total procedures, spurred by investments in technology and enhanced scheduling capabilities.
More info
Roivant Sciences Ltd. Common Shares logo
RO
Roivant Sciences Ltd. Common Shares
ROIV
Q1 2025
Reported:

Roivant posted a quiet but strategic quarter with notable advancements in its pipeline, setting the stage for an active fall and potential game-changing data from brepocitinib.

Key takeaways
  • Completed pivotal trial enrollment for brepocitinib; registrational data expected in the second half of 2025.
  • Launched a new $500 million share repurchase program after successfully completing a $1.5 billion buyback, reducing share count by over 15%.
  • Progressing clinical trials for IMVT-1402, with enrollment underway in significant indications including Grave's disease and dermatomyositis.
  • Ongoing LNP litigation with Moderna and others, with trial scheduled for March 2026.
More info
Rumble Inc. Class A Common Stock logo
RU
Rumble Inc. Class A Common Stock
RUM
Q2 2025
Reported:

Rumble Inc. demonstrated strong performance in Q2 2025, with revenue growth of 12% year-over-year and successful user retention, while announcing plans to acquire AI firm Northern Data to enhance its technological ecosystem.

Key takeaways
  • Maintained 51 million Monthly Active Users (MAUs), marking the eighth consecutive quarter above 50 million.
  • Revenue increased to $25.1 million, reflecting a 12% year-over-year rise and sequential growth.
  • Strategic partnerships established with Cumulus Media and a leading AI company, enhancing ad opportunities and tech integration.
  • Announced plans for the Rumble Wallet launch in Q3 2025, aimed at facilitating cryptocurrency tipping for creators.
  • Positive feedback received from Tether regarding the potential acquisition of Northern Data, aligning with Rumble's strategic M&A focus.
More info
RXO, Inc. logo
RX
RXO, Inc.
RXO
Q2 2025
Reported:

RXO's Q2 2025 performance exceeded expectations with adjusted EBITDA of $38 million, bolstered by strong growth in last mile and less than truckload segments despite a challenging freight market.

Key takeaways
  • Achieved adjusted EBITDA of $38 million, at the high end of guidance.
  • Last mile services saw 17% year-over-year stop growth, continuing a trend of double-digit growth for four consecutive quarters.
  • Less than truckload volume jumped 45%, significantly outperforming the overall market, which saw a decline.
  • Adjusted free cash flow conversion was robust at 58%, improving the company's cash position.
  • Continued integration of technology platforms is enhancing operational efficiency and is expected to be completed by Q3.
More info
Telephone and Data Systems, Inc. logo
TD
Telephone and Data Systems, Inc.
TDS
Q2 2025
Reported:

TDS and Array successfully closed the $4.3 billion sale of their wireless business to T-Mobile, significantly strengthening their balance sheets and enabling a renewed focus on tower and fiber operations.

Key takeaways
  • The completion of the T-Mobile transaction resulted in the assumption of $1.7 billion in debt, leaving Array with $364 million, enhancing financial flexibility.
  • A special dividend of $23 per share has been declared, with TDS receiving approximately $1.63 billion, leading to $80 million in annual interest savings after debt redemptions.
  • Leadership transitions at TDS Telecom aim to strengthen operations, with new CEO Ken Dixon bringing extensive industry experience to drive growth in fiber.
  • Array is well-positioned in the tower business, with expectations of $2 billion from upcoming spectrum sales following regulatory approvals.
  • Plans for a regular dividend are in the works for Array post-spectrum transactions, underscoring shareholder value as a priority.
More info
United States Cellular Corporat logo
US
United States Cellular Corporat
USM
Q2 2025
Reported:

TDS and Array reported robust second-quarter results, highlighted by the successful $4.3 billion sale of UScellular to T-Mobile, significantly enhancing shareholder value and improving financial flexibility.

Key takeaways
  • The completion of the T-Mobile transaction unlocks value, with $1.7 billion in debt released from the balance sheet, leaving Array with approximately $364 million.
  • A special dividend of $23 per share was declared, leading to an estimated $1.63 billion return to TDS shareholders and facilitating a $1.1 billion debt redemption.
  • Ongoing investments in the fiber and tower sectors are expected, with Array poised to explore monetization of remaining spectrum assets and implement regular dividends post-transaction completion.
  • TDS aims to maintain a conservative leverage ratio with a target of below 1.5x, ensuring financial stability and future growth opportunities.
More info
WW International, Inc. logo
WW
WW International, Inc.
WW
Q2 2025
Reported:

WeightWatchers' Q2 2025 results reflect significant strategic progress, including a 70% reduction in debt, enabling a renewed focus on innovation and investment for long-term growth.

Key takeaways
  • Successfully reduced debt by over 70%, freeing up approximately $50 million annually in interest expenses.
  • Relisted on NASDAQ under ticker WW, marking a pivotal milestone in the company's recovery.
  • Expanded leadership team to drive advancements across medical products, community experiences, and marketing initiatives.
  • Focused on restoring profitability and revenue growth through a comprehensive strategic plan anchored by four core pillars.
More info

📊 Community

See what investors are trading, holding, and sharing

🌐
All
📈
Stock
📊
ETF
🏦
Mutual Fund
🪙
Crypto
💱
Forex
# Asset Price Community % Type Currency Sector